Safety [hcpp]
utility [orgt]
Flecainide Acetate [orch, phsu]
Routine [qlco]
Care [acty]
Patients [podg]
Supraventricular tachyarrhythmias [patf]
Trial, Multicenter [resa]
Patients [podg]
Arrhythmias, supraventricular [patf]
treated [topp]
Flecainide [orch, phsu]
Conduct [inbe]
OPEN LABEL [resa]
Center [spco]
Trial [resa]
Safety [hcpp]
Efficacy [qlco]
Profile [lbpr]
Oral [spco]
Flecainide [orch, phsu]
Patients [podg]
Arrhythmias, supraventricular [patf]
Including [ftcn]
atrial tachycardias [patf]
Ectopic [spco]
Multifocal [spco]
Ventricular Tachycardias [patf]
Paroxysmal atrial flutter [patf]
Fibrillation [dsyn]
Chronic atrial fibrillation [dsyn]
Study Population [popg]
Patients [podg]
Documented [hlca]
Arrhythmias, supraventricular [patf]
treatment [ftcn]
included [ftcn]
Paroxysmal supraventricular tachycardia [dsyn]
Paroxysmal atrial flutter [patf]
Fibrillation [dsyn]
symptoms [ftcn]
days [tmco]
Chronic atrial fibrillation [dsyn]
symptoms [ftcn]
days [tmco]
Initial [tmco]
Flecainide Dose [clna]
mg% [qnco]
Twice daily [tmco]
Increased [qnco]
mg% [qnco]
4 Days [tmco]
Maximum [qnco]
mg% [qnco]
Twice daily [tmco]
Patients [podg]
treated [topp]
Receive [qlco]
Flecainide [orch, phsu]
Study [mnob]
terminated [idcn]
Response [orga]
Interim [tmco]
Reported [inpr]
Cardiac Arrhythmia [patf]
Suppression [patf]
Trial [resa]
Patients [podg]
Removed [qlco]
Study [mnob]
Study [mnob]
Termination [inpr]
Paroxysmal supraventricular tachycardia [dsyn]
Paroxysmal atrial flutter [patf]
Fibrillation [dsyn]
Chronic atrial fibrillation [dsyn]
Patients [podg]
Improved [qlco]
Flecainide [orch, phsu]
therapy [ftcn]
Eleven [qnco]
Patients [podg]
experience [menp]
Cardiac [bpoc]
Adverse Experience [fndg]
Events [evnt]
Patients [podg]
worsened [fndg]
Congestive heart failure [dsyn]
Patients [podg]
Sinus [anab]
Cardiac [bpoc]
side effects [ftcn]
APPEAR [qlco]
Patients [podg]
Chronic atrial fibrillation [dsyn]
Group [idcn]
Patients [podg]
Structural [spco]
Heart disease [dsyn]
Paroxysmal supraventricular tachycardia [dsyn]
Paroxysmal atrial flutter [patf]
Fibrillation [dsyn]
Chronic atrial fibrillation [dsyn]
Patients [podg]
Reported [inpr]
Adverse Experience [fndg]
Abnormal vision [dsyn]
Dizziness [sosy]
Headaches [sosy]
Chronic atrial fibrillation [dsyn]
Group [idcn]
Died [orgf]
considered [idcn]
Unrelated [fndg]
Flecainide [orch, phsu]
Flecainide [orch, phsu]
APPEAR [qlco]
effectiveness treatment [qlco]
Patients [podg]
Arrhythmias, supraventricular [patf]
Variety [cnce]
Mechanisms [ftcn]
APPEAR [qlco]
effective [qlco]
Patients [podg]
Paroxysmal supraventricular tachycardia [dsyn]
Efficacy [qlco]
Lowest [qlco]
side effects [ftcn]
Patients [podg]
Chronic atrial fibrillation [dsyn]
Seen [qlco]
Trial [resa]
Anti-arrhythmic [phsu]
Medication [phsu]
Patients [podg]
Context [fndg]
Cardiac Arrhythmia [patf]
Suppression [patf]
Trial [resa]
experience [menp]
Trial [resa]
Antiarrhythmic Drugs [phsu]
Patients [podg]
Chronic atrial fibrillation [dsyn]
Balance [orgf]
Benefit [qnco]
therapy [ftcn]
considered [idcn]
Initiate [idcn]
treatment [ftcn]
